ஜோசபின் ஃபெலிசியானோ News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ஜோசபின் ஃபெலிசியானோ. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ஜோசபின் ஃபெலிசியானோ Today - Breaking & Trending Today

A growing share of lung cancer is turning up in never-smokers

Jan. 26, 2021Reprints
Mandi Pike near her home in Edmond, Okla. Pike, a never-smoker, was diagnosed with lung cancer in November 2019.
Nick Oxford for STAT
Sharon Begley died of complications of lung cancer on Jan. 16, just five days after completing this article. She was a never-smoker.
Breast cancer wouldn’t have surprised her; being among the 1 in 8 women who develop it over their lifetime isn’t statistically improbable. Neither would have colorectal cancer; knowing the risk, Mandi Pike “definitely” planned to have colonoscopies as she grew older.
But when a PET scan in November 2019 revealed that Pike, a 33-year-old oil trader, wife, and mother of two in Edmond, Okla., had lung cancer she had been coughing and was initially misdiagnosed with pneumonia her first reaction was, “but I never smoked,” she said. “It all seemed so surreal.” ....

New York , United States , South Korea , Mandi Pike , Josephine Feliciano , Sharon Begley , Ahmedin Jemal , Andrew Kaufman , Ben Creelan , John Heymach , Drug Administration , Md Anderson Cancer Center , Johns Hopkins University School Of Medicine , Moffitt Cancer Center , American Cancer Society , Mount Sinai Hospital , American Cancer , Johns Hopkins University School , Mount Sinai , புதியது யார்க் , ஒன்றுபட்டது மாநிலங்களில் , தெற்கு கொரியா , மண்டி பைக் , ஜோசபின் ஃபெலிசியானோ , ஷரோன் பிச்சை , ஆண்ட்ரூ காஃப்மந் ,

Drugs create balancing act for patients with non-small cell lung cancer

E-Mail
The results of a large, retrospective study of patients who received a form of immunotherapy for non-small cell lung cancer (NSCLC) revealed that patients may get more than one immune-related side effect, and identified a correlation between these multisystem immune-related adverse events (irAEs) and improved patient survival. In fact, patients who developed two irAEs did better, in terms of delaying the time to cancer progression and overall survival, than those who developed only one irAE. According to the researchers, this new information will be helpful in discussing with patients the spectrum of immune side effects that may occur from immunotherapy and the implications for their survival. ....

Johns Hopkins Hospital , United States , North Carolina , Ohio State University , National Institutes Of Health , Dana Farber Cancer Institute , East Carolina University , Dwight Owen , Shunichi Sugawara , Christine Hann , Abdul Rafeh Naqash , Gregory Otterson , David Ettinger , Paul Walker , Jiajia Zhang , Bairavi Shankar , Julie Brahmer , Josephine Feliciano , Biagio Ricciuti , Patrick Forde , Sandip Patel , Jarushka Naidoo , Kristen Marrone , James Comprehensive Cancer Center , University Of Perugia , Kimmel Cancer Center ,